Vor Biopharma Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Rati Pinhe, Joyce Zhou and Priyanka Grover. Our next presenting company is Vor and presenting on behalf of the company, we have CEO Jean-Paul Kress.
Thank you, Anupam and good morning everyone. Pleasure to be here and to update you on our progress at Vor. First, I'd like to say that I will be making forward-looking statements. This is our disclosure slide. I'll let you read it quickly.
And at Vor, we have the ambition to redefine the way we treat autoimmune B-cell-mediated diseases. And we want to improve the standard of care, as we pivoted the company mid '25 to an autoimmune powerhouse from a cell therapy company. So it's a brand new Vor, we call it Vor 2.0.
And for doing so, we in-licensed what we think is one of the most
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
